Biopharma · FDA Approvals · Stock
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA B…
Dated catalysts for ADMA, including recently decided ones.
Nothing scheduled in this window.
Every first-hand event for ADMA, newest first.
ADMA Biologics Receives Constructive FDA Feedback on SG-001 Pre-IND Meeting Package
ADMA received constructive FDA feedback on its SG-001 pre-IND meeting package regarding the proposed clinical development strategy and planned clinical study. The FDA indicated that the proposed assay would be acceptable for product testing subject to validation. ADMA intends to incorporate the recommendations into the final clinical protocol and advance preparations for an IND submission.
ADMA Biologics: FDA expands ASCENIV label to pediatric PI patients ≥2 years
FDA approved the sBLA that removes the prior age restriction, now allowing ASCENIV use in PI patients two years of age and older. The expanded label fulfills the post-marketing pediatric study commitment and broadens the addressable patient population from age 12+ to age 2+.
Companies in the same sector closest to ADMA in market value.